Clinical Trials Logo

Clinical Trial Summary

This clinical trial is examining the effect of 4-week aspirin therapy on platelet transcriptome in persons at high-risk for myocardial infarction or stroke due to family history of early-onset coronary artery disease.


Clinical Trial Description

Platelet aggregation can initiate thrombosis on ulcerated arterial plaques resulting in acute coronary syndrome (ACS). There is large variation in platelet aggregation between individuals. As the genetic message to the cell machinery is conveyed through its transcriptome, we hypothesize that much of the variability in platelet function can be explained by transcriptome changes including differences in gene or isoform expression, altered splicing events, or allele-specific expression. Moreover, aspirin modifies gene expression in several cells, but whether it also affects platelet transcriptome has not yet been studied. Our goal is to characterize the platelet transcriptome and identify genes that are up- or down-regulated after 4-week aspirin therapy. A major strength of our study is that it enrolls individuals from European Americans and African Americans and thus will have the ability to study similarities and differences between the two. The study will produce innovative comparative genomic/platelet phenotype data and will provide a potential pharmacogenomic and diagnostic template for the future discovery of novel antiplatelet regimens to prevent thrombosis-related cardiovascular disease events. ;


Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


NCT number NCT01894555
Study type Interventional
Source Johns Hopkins University
Contact
Status Completed
Phase Phase 4
Start date January 2013
Completion date August 2014

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Completed NCT02616497 - ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS) Phase 4
Not yet recruiting NCT02898467 - Atherothrombosis Markers in Diabetics N/A
Completed NCT01225562 - Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Phase 3
Completed NCT03943966 - In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer N/A
Completed NCT01805063 - Effect of Fire Suppression and Emergency Duties on Vascular Function
Terminated NCT01788930 - Aspirin Resistance and Sleep Apnea in Type-2 Diabetic Patients N/A
Recruiting NCT03062319 - Optimal Antithrombotic Therapy in Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation and Atherothrombosis Phase 4
Completed NCT01813032 - Comparison of Vascular Function in Emergency Service Professionals
Completed NCT01812317 - Effect of Real-fire Training on Vascular Function N/A